Pediatrix's Surge Shows Gains Amid Growing Headwinds

A look at the forces fueling recent returns and the risks that could shape performance over the next 12‑18 months

MD Pediatrix Medical Group, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

MD — Pediatrix Medical Group, Inc.

Healthcare · Medical - Care Facilities $1.84B · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

No Moat (Commodity)

🔒 Unknown

📈 Pricing Power

Strong

🏆 Market Position Competitor

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue -4.9% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

11.0x P/E 2.1x P/B 7.7x EV/EBITDA

⚖️ Tier

Fair Value

📊 Beta 0.71 (Low Volatility)

Pediatrix Medical Group, Inc. operates a nationwide network of pediatric and neonatal specialty hospitals and outpatient centers, delivering around $1.9 billion in revenue primarily through fee‑for‑service contracts with insurers and government payors. The business is asset‑heavy, owning the facilities it staffs, which anchors its pricing power despite operating in a largely commoditized market. With an operating margin of 12.1% and net margin of 8.6%, the company generates solid cash flow at a modest 11× forward P/E, positioning it as a fair‑value, value‑style investment. However, revenue is contracting (-4.9% YoY) and growth trends are negative, reflecting broader demographic headwinds in birth rates and heightened competition.

Defensive demand profile: Pediatric and neonatal care is largely recession‑proof, giving Pediatrix a stable cash‑flow base even as macro conditions fluctuate.
Pricing resilience despite commodity status: Strong pricing power stems from limited specialty alternatives for newborn intensive care, allowing the firm to sustain margins above industry averages.
Asset intensity limits scalability: Heavy capital commitments to hospitals constrain rapid expansion and amplify fixed‑cost risk if patient volumes decline further.
Valuation attractiveness with downside risk: At a 11× P/E the stock trades near fair value, but the declining revenue trajectory introduces a material earnings‑risk premium that investors must price in.

Equity Performance & Market Positioning

Pediatrix Medical Group, Inc. (MD) — Stock Returns

Recent Performance

1.8%

1 Month

vs S&P +1.5

14.5%

3 Month

vs S&P +4.9

-2.9%

6 Month

vs S&P -10.7

5.7%

YTD

vs S&P -2.2

62.7%

1 Year

vs S&P +39.0

The stock outperformed the S&P 500 over the past month, delivering a 1.8% gain versus the index's 1.5%, indicating modest short‑term resilience despite broader market volatility.
A 14.5% three‑month rally, more than double the S&P's 4.9% gain, suggests that recent operational or earnings news may have spurred investor optimism and attracted momentum capital.
The six‑month return of -2.9% still beat the broader market's -10.7% decline, highlighting the stock's defensive characteristics in a bearish environment.
Year‑to‑date performance of +5.7% versus the S&P's -2.2% underscores that MD has been a relative safe haven this year, likely benefiting from its niche pediatric care model amid macro uncertainty.

Long-Term Performance (Annualized)

18.6%

3 Year

vs S&P -1.9

-7.0%

5 Year

vs S&P -18.9

-10.4%

10 Year

vs S&P -23.8

4.8%

Full History

vs S&P -3.4

Over the past three years, MD delivered an annualized return of +18.6% while the S&P fell -1.9%, reflecting consistent outperformance driven by steady revenue expansion and high-margin specialty services.
The five‑year annualized return of -7.0% remains less negative than the S&P's -18.9%, indicating that despite a downturn, MD has preserved relative value better than the broader market.
A ten‑year annualized decline of -10.4% versus the S&P's -23.8% demonstrates long‑term resilience; the stock’s slower erosion is likely due to its defensive healthcare niche and recurring reimbursement streams.
The full‑history annualized gain of +4.8%, while modest, still outpaces the S&P's -3.4%, suggesting that over multiple market cycles MD has generated incremental shareholder value.

Highlight

The 1‑year total return of +62.7%—far exceeding the S&P's 39.0% gain—signals a powerful compounding effect, driven by strong earnings growth and expanding market share in neonatal services, making MD a standout performer for growth‑oriented investors.

Watch Out

The negative long‑term trajectory—especially a 10‑year annualized decline of -10.4%—signals structural headwinds such as reimbursement pressure and potential regulatory changes; if average earnings growth falls below inflation, the stock could underperform further, eroding its defensive premium.

Equity Performance & Market Positioning

Pediatrix Medical Group, Inc. (MD) — Risk & Smart Money

Risk Profile

29.8%

Volatility (20D)

0.70

Beta

1.95

Sharpe Ratio

-23.8%

Max Drawdown (1Y)

52

RSI (14)

82%

52-Week Range

The stock’s annualized volatility of 29.8% is markedly higher than the S&P 500 average (~15%), indicating price swings that could amplify both gains and losses for investors.
A beta of 0.7 suggests MD moves less aggressively than the broader market, providing a modest defensive tilt despite its high absolute volatility.
The Sharpe ratio of 1.9 is well above the typical benchmark of 1.0, implying that the company has generated strong risk‑adjusted returns relative to its volatility.
A maximum drawdown of -23.8% shows the deepest historical loss from peak to trough, highlighting a potential downside ceiling that investors must be prepared to absorb during market stress.

Smart Money Positioning

96.8%

Institutional Ownership

-0.2% QoQ

2.40

Insider Buy/Sell

Institutional ownership sits at 96.80%, reflecting near‑complete confidence from professional investors and suggesting a high barrier to large share sales without market impact.
The negligible institutional change of -0.15% over the recent reporting period signals stability in holdings, implying that institutions are neither rapidly exiting nor aggressively accumulating positions.
Insider buying exceeds selling with a net balance of +2.40%, indicating management’s alignment with shareholder interests and potentially foreshadowing positive internal outlooks.
The RSI at 51.6 places the stock just above neutral, suggesting there is no immediate overbought pressure from smart money and that momentum remains modest.

Watch Out

Despite overwhelming institutional ownership, the slight -0.15% reduction hints at a marginal pullback; if this trend accelerates beyond 1% monthly, it could signal emerging skepticism among smart money, potentially precipitating increased volatility given the already high price swing environment.

Revenue, Earnings & Margin History

Pediatrix Medical Group, Inc. (MD) — Revenue & Growth

Revenue & Growth

Revenue declined 4.9% YoY to $1.9 B, indicating a contraction in the neonatal and perinatal services market that underpins Pediatrix's core franchise.
The three‑year CAGR of -1.0% shows the revenue decline is not a one‑off event but a persistent downward trend, eroding top‑line momentum and pressuring valuation multiples.
EPS of $1.94 remains modest relative to peers, reflecting that earnings are being dragged down by lower volume rather than cost inefficiencies, which limits upside potential for growth‑oriented investors.
Zero R&D spend underscores a business model focused on service delivery rather than product innovation, meaning organic revenue expansion must come from volume or pricing power alone.

Highlight

The combination of a sub‑5% YoY revenue drop and a negative three‑year CAGR signals a deteriorating top line that challenges the sustainability of current earnings levels and suggests limited near‑term growth catalysts.

Margin Evolution

Gross margin stands at 24.7%, comfortably above many healthcare service peers, indicating strong pricing leverage on clinical services despite volume declines.
Operating margin of 12.1% reflects efficient cost control; the gap between gross and operating margins suggests that SG&A expenses are well managed relative to revenue.
Net margin of 8.6% is healthy for a provider‑focused firm, showing that after taxes and interest the business retains a solid profit cushion even in a shrinking market.
Free cash flow conversion of 13.2% demonstrates that a meaningful portion of earnings translates into cash, supporting dividend sustainability and potential debt reduction.

Watch Out

The net margin, while currently respectable at 8.6%, is vulnerable to further revenue erosion; a continued 5% annual decline would compress net income by roughly $100 M over two years, potentially forcing cost cuts that could impair service quality and long‑term growth prospects.

Revenue, Earnings & Margin History

Pediatrix Medical Group, Inc. (MD) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

-1.0%

5Y

+2.0%

💰 EPS

3Y

+34.9%

Revenue declined 4.9% YoY to $1.9 B, indicating a contraction in the neonatal and perinatal services market that underpins Pediatrix's core franchise.
The three‑year CAGR of -1.0% shows the revenue decline is not a one‑off event but a persistent downward trend, eroding top‑line momentum and pressuring valuation multiples.
EPS of $1.94 remains modest relative to peers, reflecting that earnings are being dragged down by lower volume rather than cost inefficiencies, which limits upside potential for growth‑oriented investors.
Zero R&D spend underscores a business model focused on service delivery rather than product innovation, meaning organic revenue expansion must come from volume or pricing power alone.

Profitability & Return on Capital

Pediatrix Medical Group, Inc. (MD) — DuPont & Efficiency

DuPont Decomposition (2025)

19.1%

ROE

=

8.6%

Net Margin

×

0.85x

Asset Turnover

×

2.6x

Eq. Multiplier

ROE rose from 13.8% to 19.1%, driven primarily by a 39% increase in asset turnover (0.61 → 0.85), indicating the firm is generating more revenue per dollar of assets.
The profit margin fell from 12.1% to 8.6%, reflecting higher cost pressure or pricing compression that offsets some of the upside from greater sales efficiency.
Equity multiplier climbed from 1.87 to 2.59, showing a deliberate shift toward leverage; each dollar of equity now supports $2.59 of assets, amplifying ROE but also raising financial risk.
Despite margin erosion, the combined effect of higher turnover and leverage more than compensates, delivering a net ROE increase of 5.3 percentage points, which signals improved operational scaling.

Highlight

The 39% jump in asset turnover is the standout driver of ROE growth, demonstrating that Pediatrix is extracting significantly more revenue from its existing asset base—a positive sign for scalability and competitive positioning.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	19.1	8.6	0.85	2.59	14.0	12.9	7.4
2024	-13.0	-4.9	0.94	2.81	-4.5	-4.0	-4.6
2023	-7.1	-3.0	0.90	2.61	0.4	0.4	-2.7
2022	7.4	3.4	0.84	2.63	10.2	9.0	2.8
2021	14.6	6.9	0.70	3.04	9.8	8.8	4.8
2020	-106.6	-45.9	0.52	4.48	3.6	3.4	-23.8
2019	-99.9	-84.2	0.43	2.77	9.4	4.8	-36.1
2018	8.7	7.4	0.61	1.92	8.0	8.2	4.5
2017	10.4	9.3	0.59	1.91	8.6	8.8	5.5
2016	11.8	10.2	0.60	1.93	11.4	11.6	6.1
2015	13.8	12.1	0.61	1.87	13.9	13.4	7.4

ROIC stands at 14.0%, comfortably above the company's weighted average cost of capital, indicating value creation on invested capital.
The cash conversion cycle (CCC) of 37 days reflects efficient working‑capital management, with inventory and receivables turned over quickly relative to industry peers.
Higher asset turnover (0.85) aligns with the strong ROIC, showing that incremental sales are being generated without proportionate capital outlays.
Leverage has risen (equity multiplier 2.59), which can boost ROIC if additional debt is deployed in high‑return projects; current returns suggest disciplined use of borrowed funds.

Watch Out

Margin compression to 8.6% reduces operating cash flow, and if cost pressures persist it could lower ROIC below the cost of capital; a 3.5 percentage‑point margin drop translates to roughly $12 M less EBIT on a $340 M revenue base, eroding the cushion for capital efficiency.

Profitability & Return on Capital

Pediatrix Medical Group, Inc. (MD) — ROIC & Cash Conversion

Return on Invested Capital

Current14.0%

Mean7.7%

Min-4.5%

Max14.0%

Range18.4pp

Cash Conversion Cycle

Current37d

Mean48d

Min34d

Max79d

ROIC stands at 14.0%, comfortably above the company's weighted average cost of capital, indicating value creation on invested capital.
The cash conversion cycle (CCC) of 37 days reflects efficient working‑capital management, with inventory and receivables turned over quickly relative to industry peers.
Higher asset turnover (0.85) aligns with the strong ROIC, showing that incremental sales are being generated without proportionate capital outlays.
Leverage has risen (equity multiplier 2.59), which can boost ROIC if additional debt is deployed in high‑return projects; current returns suggest disciplined use of borrowed funds.

Profitability & Return on Capital

Pediatrix Medical Group, Inc. (MD) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

0d

Inventory Days

+

46d

Receivables Days

+

14d

Fixed Asset Days

≈

428d

Total Asset Days

(0.85x turn)

Cash Conversion Cycle (2025)

0d

Inventory Days

+

46d

Receivables Days

−

9d

Payables Days

=

37d

CCC

Turnover & Days History

Year	Total Asset Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	428	46	14	9	37
2024	390	49	14	11	39
2023	406	51	27	8	43
2022	435	55	26	8	47
2021	520	60	26	10	51
2020	705	51	28	17	34
2019	850	89	26	10	79
2018	594	51	13	4	46
2017	619	53	13	5	48
2016	612	57	12	5	52
2015	597	58	11	4	54

ROE rose from 13.8% to 19.1%, driven primarily by a 39% increase in asset turnover (0.61 → 0.85), indicating the firm is generating more revenue per dollar of assets.
The profit margin fell from 12.1% to 8.6%, reflecting higher cost pressure or pricing compression that offsets some of the upside from greater sales efficiency.
Equity multiplier climbed from 1.87 to 2.59, showing a deliberate shift toward leverage; each dollar of equity now supports $2.59 of assets, amplifying ROE but also raising financial risk.
Despite margin erosion, the combined effect of higher turnover and leverage more than compensates, delivering a net ROE increase of 5.3 percentage points, which signals improved operational scaling.

Balance Sheet & Cash Flow Health

Pediatrix Medical Group, Inc. (MD) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$2247M	$1381M	$866M	$660M	$285M	$375M	$764M	$459M
2024	$2153M	$1388M	$765M	$662M	$432M	$230M	$640M	$434M
2023	$2220M	$1371M	$849M	$702M	$628M	$73M	$483M	$389M
2022	$2348M	$1456M	$892M	$717M	$707M	$10M	$428M	$427M
2021	$2723M	$1826M	$896M	$1066M	$678M	$387M	$841M	$427M
2020	$3348M	$2600M	$747M	$1805M	$681M	$1124M	$1549M	$444M
2019	$4146M	$2647M	$1499M	$1793M	$1685M	$108M	$732M	$542M
2018	$5935M	$2847M	$3088M	$1975M	$1938M	$37M	$657M	$469M
2017	$5867M	$2801M	$3066M	$1853M	$1793M	$60M	$627M	$438M
2016	$5339M	$2579M	$2761M	$1706M	$1650M	$56M	$587M	$408M
2015	$4547M	$2109M	$2438M	$1275M	$1223M	$52M	$528M	$396M

Liquidity & Solvency

7/9

Piotroski F-Score

Strong

2.1

Altman Z-Score

Gray

The current ratio of 1.66 exceeds the 1.5 benchmark, indicating that Pediatrix holds $1.66 in short‑term assets for every $1 of current liabilities, which provides a comfortable cushion against liquidity shocks.
A debt‑to‑equity ratio of 0.76 is well below the 1.0 threshold, reflecting a conservative capital structure and limiting financial risk should earnings volatility arise.
Interest coverage at 6.43x comfortably surpasses the 5‑times guideline, showing that operating earnings are more than sufficient to meet interest obligations and reducing default probability.
Free cash flow represents 13.20% of revenue, well above the 10% strong‑performance line, indicating that a sizable portion of sales is converted into discretionary cash for reinvestment or debt reduction.

Balance Sheet & Cash Flow Health

Pediatrix Medical Group, Inc. (MD) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks
2025	$271M	$-18M	$-107M	$-18M	$253M	$-87M
2024	$207M	$-35M	$-14M	$-22M	$185M	$-2M
2023	$137M	$-48M	$-26M	$-33M	$104M	$-1M
2022	$167M	$-57M	$-488M	$-30M	$137M	$-89M
2021	$77M	$-53M	$-760M	$-32M	$44M	$-5M
2020	$205M	$816M	$-4M	$-29M	$176M	$-8M
2019	$358M	$102M	$-393M	$-19M	$338M	$-145M
2018	$290M	$-143M	$-171M	$-49M	$241M	$-302M
2017	$511M	$-577M	$90M	$-49M	$462M	$-70M
2016	$444M	$-821M	$382M	$-39M	$405M	$-62M
2015	$369M	$-848M	$483M	$-27M	$342M	$-235M

Cash Flow Trends

A Piotroski F‑score of 7 out of 9 indicates strong underlying financial health, with most criteria—such as positive net income growth and improving asset turnover—met, suggesting sustainable earnings quality.
The Altman Z‑score of 2.09, while not in the safe zone (>2.99), is above the distress threshold (<1.81), reflecting a moderate but watchable risk profile that investors should monitor alongside cash flow trends.
Operating cash flow exceeds net income by a factor of 1.64, confirming that earnings are well‑backed by cash generation and reducing the likelihood of earnings manipulation.

Balance Sheet & Cash Flow Health

Pediatrix Medical Group, Inc. (MD) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑score of 7 out of 9 indicates strong underlying financial health, with most criteria—such as positive net income growth and improving asset turnover—met, suggesting sustainable earnings quality.
The Altman Z‑score of 2.09, while not in the safe zone (>2.99), is above the distress threshold (<1.81), reflecting a moderate but watchable risk profile that investors should monitor alongside cash flow trends.
Operating cash flow exceeds net income by a factor of 1.64, confirming that earnings are well‑backed by cash generation and reducing the likelihood of earnings manipulation.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +62.7%

vs S&P +39.0pp

Revenue 3Y CAGR

▼ -1.0%

5Y: +2.0%

Net Margin

8.6%

▲ 3Y ago: 3.4%

ROIC

14.0%

▲ 3Y ago: 10.2%

FCF Margin

13.2%

▲ 3Y ago: 7.0%

Piotroski

7/9

Strong

Pediatrix Medical Group delivered an extraordinary 62.66% total return over the past year, outpacing the S&P 500 by 39 percentage points despite a modest 4.92% revenue decline and a negative five‑year earnings trajectory. The company’s profitability remains robust, with an 8.64% net margin, ROE of 19.1%, and ROIC of 13.96%, underscoring strong pricing power and efficient capital deployment in its specialty neonatal services. A solid balance sheet—current ratio of 1.66, debt‑to‑equity of 0.76, and interest coverage of 6.4x—provides ample liquidity to weather the revenue contraction. However, the high volatility (29.8% annualized) and a max drawdown of 23.84% indicate that price swings can be sharp, while the negative five‑year CAGR signals longer‑term growth challenges. Together, these dynamics suggest a high‑conviction upside play if the firm can reverse revenue trends, but investors must monitor cash conversion and debt service capacity.

✅ Strengths

Exceptional 1‑year total return of 62.66% with a Sharpe ratio of 1.95 signals superior risk‑adjusted performance relative to peers.
Strong profitability metrics—net margin 8.64%, ROE 19.1%, and ROIC 13.96%—demonstrate the ability to generate high returns on capital despite shrinking revenues.
Robust balance sheet: current ratio of 1.66 and debt‑to‑equity of 0.76 keep leverage moderate, while an interest coverage ratio of 6.4x ensures comfortable debt servicing.
High institutional ownership at 96.8% aligns management incentives with shareholders and reduces the likelihood of adverse corporate actions.

⚠️ Risks

Revenue is down 4.92% YoY and the three‑year CAGR is -1.0%, indicating a weakening top line that could pressure future earnings if not reversed.
Negative five‑year annualized return of -6.97% reflects longer‑term underperformance, suggesting structural challenges in growth or market positioning.
Volatility of 29.84% and a max drawdown of 23.84% expose investors to significant price swings, which could trigger stop‑loss orders and amplify downside risk during market stress.

MD

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.